Johannes Gutenberg-Universität Mainz

Ganymed Pharmaceuticals Ag

Ganymed Pharmaceuticals Gmbh

Astellas Pharma Gmbh

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Tron Translationale Onkologie an Der Universitatsm

Tron - Translationale Onkologie an Der Universitatsmedizin Der Johannes

Stefan Woll

Ugur Sahin

Ozlem Tureci

Michael Koslowski

Korden Walter

Maria Kreuzberg

Bernd Hubner

Michael Erdeljan

Rita Mitnacht-Kraus

Stefan Jacobs

Michael Weichel

Cornelia Heinz

Özlem Türeci

Gerd Helftenbein

Gabriela-Elena Oprea

Özlem Tureci

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Antibodies against claudin 18.2 useful in cancer diagnosis

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies for treatment of cancer expressing claudin 6

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies specific for claudin 6 (CLDN6)

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.

Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

Methods and compositions for diagnosis and treatment of cancer

Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma

Antibodies for treatment of cancer

Growing community of inventors

Nackenheim, Germany

Stefan Woll